Astellas Pharma Articles
Mylan gets US approval for copy version of Astellas’ immunosuppressant Prograf; Teva files complaint over Copaxone patents
22 September 2010
Basilea told Janssen-Cilag will stop Swiss sales of Zevetera; initiates Ph III testing of isavuconazole with Astellas
13 September 2010
In Japan, Celgene’s Revlimid gets approval; Astellas to file degarelix and inks vaccine deal with UMN
23 August 2010
Two of Japan’s top drugmakers - Takeda and Astellas - expect profits decline as patent expiries bite
13 May 2010
Urology and transplantation will drive future growth as Astellas begins move into oncology
21 April 2010
Astellas and Medivation see strong Ph I/II data on prostate cancer drug candidate MDV3100
16 April 2010
Ranbaxy back in black in fourth quarter as US sales soar
26 February 2010
Japan’s drug pricing reform will trigger industry reorganization, claims FPMAJ chief; Pharma R&D spend
18 January 2010
Ambit sells rights for FLT3 Kinase inhibitors to Japan’s Astellas for up to $390 million
18 December 2009
UK regulatory agency clears prostate drug Flomax for OTC use; generic competition due next year in USA
14 December 2009
Japanese filing of gabapentin enacarbil for RLS triggers $5 million milestone from Astellas to XenoPort
20 November 2009
Astellas acquires rights to Medivation’s MDV3100 for prostate cancer in up to $765 million deal
27 October 2009
Boehringer Ingelheim launches co-pay rebate program for Viramune in USA; settles with Impax over Flomax
7 October 2009
US FDA approves Theravance and Astellas’ Vibativ
14 September 2009
Astellas to co-promote AstraZeneca’s Symbicort in Japan
4 August 2009
Strong yen halts Astellas' sales growth
27 May 2009
CV board rejects Astellas bid for second time
2 March 2009
GSK/XenoPort resubmit NDA in RLS
19 January 2009
Crisis in CEE pharma innovative market
22 December 2008
Astellas Europe appoints Kay Spiller as VP of marketing
15 December 2008
Japan's doctors want new drugs developed
8 December 2008
Astellas looking to overtake Takeda's leading share of home market with newer products
15 September 2008
Astellas drug development to move to USA
14 April 2008
Japan stock market week to March 10, 2008
17 March 2008
Astellas to establish US global development base
10 March 2008
Astellas' Mycamine gets CHMP OK
3 March 2008
FDA approves Astellas' Mycamine sNDA
28 January 2008
Vaprisol raises sodium levels in hyponatremia
5 November 2007
Strong Ph III data for telavancin in cSSSI
1 October 2007
Astellas/Cardiome's drug gets longer FDA review
10 September 2007
Astellas reorganizes European business
13 August 2007
Astellas and Pfizer to sell Celecox in Japan
25 June 2007
Japan's Chuikyo drug price reform timetable
18 June 2007
Astellas/NeuroSearch initiate Ph Ib trial of ACR16
16 April 2007
MorphoSys licenses HuCAL to Astellas
9 April 2007
13 new drugs added to Japan's NHI list
19 March 2007
New Vaprisol indication ushers in age of aquaresis
12 March 2007
Astellas' FK506 gets positive opinion from CHMP
5 March 2007
FDA accepts NDA for Cardiome/Astellas' vernakalant
26 February 2007
Kirin and Astellas to develop CD40 MAb
29 January 2007
Astellas launches 100mg Mycamine
22 January 2007
Astellas submits sNDA for Mycamine
8 January 2007
Astellas and Temmler in asset transfer deal
22 December 2006
QLT
11 December 2006
Japan's generic drugs market expected to grow 8.8% from 2006 to 2008
27 November 2006
Astellas' fiscal 06/07 first-half net sales rise 5%
20 November 2006
Astellas predicts 60.6B yen half-year income
6 November 2006
Stock Commentary - Tokyo week to Oct 2, 2006
9 October 2006
Astellas screens target from Metabolex' gene database
18 September 2006
Astellas ends FK481 R&D deal with Servier
5 June 2006
Top appointments at Astellas Pharma
8 May 2006
Astellas spins-out API business into new firm
10 April 2006
Astellas to acquire Biogen Idec's Amevive
10 April 2006
Prograf gets FDA OK for heart transplant care
10 April 2006
Astellas to acquire Biogen Idec's Amevive
10 April 2006
Taisho denies purchase speculation
20 February 2006
Astellas Pharma's Vaprisol gains FDA approval
9 January 2006
Apoxis acquires rights for anticancer drug FK866
19 December 2005
Theravance and Astellas finalize telavancin deal
12 December 2005
CV Thera/Astellas's regadenoson meets Ph III endpoint
22 August 2005
Astellas launches oral Harnal
20 June 2005
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
